T-bet compositions and methods of use thereof
Isolated nucleic acid molecules encoding T-bet, and isolated T-bet polypeptides, are provided. The invention further provides antisense nucleic acid molecules, recombinant expression vectors containing a nucleic acid molecule of the invention, host cells into which the expression vectors have been introduced and non-human transgenic animals carrying a T-bet transgene. The invention further provides T-bet fusion proteins and anti-T-bet antibodies. Methods of using the T-bet compositions of the invention are also disclosed, including methods for detecting T-bet expression and/or activity in a biological sample, methods of modulating T-bet expression and/or activity in a cell, and methods for identifying agents that modulate the expression and/or activity of T-bet.
1. A method for identifying a compound that modulates the activity of a T-bet polypeptide, comprising providing a recombinant cell that comprises an expression vector encoding the T-bet polypeptide, wherein the T-bet polypeptide binds a consensus T-box site in DNA and induces IFN-γ production in CD4+ cells, and wherein said expression vector comprises:
i) a nucleic acid molecule which hybridizes to the full length complement of the nucleic acid molecule set forth in SEQ ID NO:1 in 6×SSC at 45° C., followed by one or more washes in 0.2×SSC, 0.1% SDS at 65° C.; or
ii) a nucleic acid molecule which hybridizes to the full length complement of the nucleic acid molecule set forth in SEQ ID NO:3 in 6×SSC at 45° C., followed by one or more washes in 0.2×SSC, 0.1% SDS at 65° C.; or
iii) a nucleic acid molecule encoding a polypeptide with at least 90% amino acid identity to SEQ ID NO:2; or
iv) a nucleic acid molecule encoding a polypeptide with at least 90% amino acid identity to SEQ ID NO:4;
said recombinant cell further comprising:
v) a nucleic acid molecule comprising a Tbox binding site to which the T-bet polypeptide binds;
contacting the recombinant cell with a test compound; and
evaluating the effect of the test compound by determining the binding of the T-bet polypeptide to the nucleic acid molecule comprising the T-box binding site in the presence and absence of the test compound, to thereby identify a compound that modulates the activity of the T-bet polypeptide.
2. The method of claim 1 , wherein the expression vector comprises a nucleic molecule encoding the polypeptide of SEQ ID NO: 4.
3. The method of claim 1 , wherein the expression vector comprises a nucleic acid molecule comprising the nucleotide sequence of SEQ ID NO:1.
4. The method of claim 1 , wherein the expression vector comprises a nucleic acid molecule comprising the nucleotide sequence of SEQ ID NO:3.
5. The method of claim 1 , wherein the nucleic acid molecule of v) is an IL-2 promoter.
6. The method of claim 2 , wherein the nucleic acid molecule of v) is an IFN-γ promoter.
7. The method of claim 1 , further comprising determining the effect of the test compound on an immune response in a non-human animal, comprising administering the test compound to the animal and determining the effect of test compound on an immune response, to thereby identify a compound that modulates an immune response.
8. The method of claim 1 , wherein the activity of the polypeptide is enhanced.
9. The method of claim 1 , wherein the activity of the polypeptide is inhibited.
10. The method of claim 1 , wherein the test compound is selected from the group consisting of: nucleic acid molecules, peptides, and small molecules.
11. The method of claim 1 , further comprising determining the effect of the test compound on T or B cell responsiveness in a cell-based assay.
12. The method of claim 11 , wherein T or B cell responsiveness is determined by measuring and effect of the test compound on an outcome selected from the group consisting of: IgG class switching, Th1 cell development, Th2 cell development, and B lymphocyte function.
13. The method of claim 1 , wherein the nucleic acid molecule of v) comprises a reporter gene operably linked to a T-bet responsive promoter comprising the T-box binding site, and the ability of the T-bet polypeptide to bind to the promoter is determined by evaluating the expression of the reporter gene in the presence and absence of the test compound.
14. The method of claim 13 , wherein the reporter gene is selected from the group consisting of IL-2 and IFN-γ.
15. The method of claim 14 , wherein the reporter gene is IFN-γ.
16. The method of claim 13 , wherein the reporter gene is selected from the group consisting of genes that encode: chloramphenicol acetyltransferase, beta-galactosidase, alkaline phosphatase and luciferase.
17. The method of claim 1 , wherein the expression vector comprises a nucleic molecule encoding the polypeptide of SEQ ID NO: 2.
18. The method of claim 17 , wherein the nucleic acid molecule of v) is an IL-2 promoter.
19. The method of claim 17 , wherein the nucleic acid molecule of v) is an IFN-γ promoter.
20. The method of claim 17 , further comprising determining the effect of the test compound on an immune response in a non-human animal, comprising administering the test compound to the animal and determining the effect of test compound on an immune response, to thereby identify a compound that modulates an immune response.
21. The method of claim 17 , wherein the activity of the polypeptide is enhanced.
22. The method of claim 17 , wherein the activity of the polypeptide is inhibited.
23. The method of claim 17 , wherein the test compound is selected from the group consisting of: nucleic acid molecules, peptides, and small molecules.
24. The method of claim 17 , further comprising determining the effect of the test compound on T or B cell responsiveness in a cell-based assay.
25. The method of claim 24 , wherein T or B cell responsiveness is determined by measuring and effect of the test compound on an outcome selected from the group consisting of: IgG class switching, Th1 cell development, Th2 cell development, and B lymphocyte function.
26. The method of claim 17 , wherein the nucleic acid molecule of v) comprises a reporter gene operably linked to a T-bet responsive promoter comprising the T-box binding site, and the ability of the T-bet polypeptide to bind to the promoter is determined by evaluating the expression of the reporter gene in the presence and absence of the test compound.
27. The method of claim 26 , wherein the reporter gene is selected from the group consisting of IL-2 and IFN-γ.
28. The method of claim 27 , wherein the reporter gene is IFN-γ.
29. The method of claim 26 , wherein the reporter gene is selected from the group consisting of genes that encode: chloramphenicol acetyltransferase, beta-galactosidase, alkaline phosphatase and luciferase.
30. A method for identifying a compound that modulates the activity of a T-bet polypeptide, comprising providing a recombinant cell that comprises an expression vector encoding the T-bet polypeptide, wherein the T-bet polypeptide binds a consensus T-box site in DNA and induces IFN-γ production in CD4+ cells, and wherein said expression vector comprises:
i) a nucleic acid molecule which hybridizes to the full length complement of the nucleic acid molecule set forth in SEQ ID NO:1 in 6×SSC at 45° C., followed by one or more washes in 0.2×SSC, 0.1% SDS at 65° C.; or
ii) a nucleic acid molecule which hybridizes to the full length complement of the nucleic acid molecule set forth in SEQ ID NO:3 in 6×SSC at 45° C., followed by one or more washes in 0.2×SSC, 0.1% SDS at 65° C.; or
iii) a nucleic acid molecule encoding a polypeptide with at least 90% amino acid identity to SEQ ID NO:2; or
iv) a nucleic acid molecule encoding a polypeptide with at least 90% amino acid identity to SEQ ID NO:4;
said recombinant cell further comprising:
v) a tec kinase molecule to which the T-bet polypeptide binds;
contacting the recombinant cell with a test compound; and
evaluating the effect of the test compound by determining the binding of the T-bet polypeptide to the tec kinase molecule in the presence and absence of the test compound, to thereby identify a compound that modulates the activity of the T-bet polypeptide.
31. The method of claim 30 , wherein the tec kinase is selected from the group consisting of ITK and rlk.